Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ligand Pharm (LGND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,568,275
  • Shares Outstanding, K 21,254
  • Annual Sales, $ 251,450 K
  • Annual Income, $ 143,320 K
  • 36-Month Beta 1.40
  • Price/Sales 10.22
  • Price/Cash Flow 15.88
  • Price/Book 4.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.90
  • Number of Estimates 1
  • High Estimate 0.90
  • Low Estimate 0.90
  • Prior Year 1.38
  • Growth Rate Est. (year over year) -34.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
98.56 +22.63%
on 01/16/19
131.00 -7.74%
on 01/16/19
-10.91 (-8.28%)
since 01/15/19
3-Month
98.56 +22.63%
on 01/16/19
166.52 -27.42%
on 11/30/18
-31.05 (-20.44%)
since 11/15/18
52-Week
98.56 +22.63%
on 01/16/19
278.62 -56.62%
on 10/01/18
-36.32 (-23.11%)
since 02/15/18

Most Recent Stories

More News
Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars

Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.

MGNX : 21.84 (+3.41%)
LGND : 120.86 (-0.02%)
INCY : 84.15 (+0.88%)
GILD : 67.59 (+1.84%)
SGEN : 71.48 (+4.24%)
REGN : 423.97 (+2.17%)
Merrimack (MACK) Stock Up Year to Date: Is a Rebound Likely?

Merrimack (MACK) regains its status as a development-stage biopharma company after the sale of its sole marketed product Onivyde in 2017.

LGND : 120.86 (-0.02%)
CELG : 90.69 (+0.01%)
ADRO : 4.05 (+10.05%)
MACK : 5.86 (-0.34%)
AMAG Q4 Loss Narrower Than Expected, Revenues Lag Estimates

AMAG encourages with narrower-than-expected loss in Q4 while revenues fall shy of estimates.

CELG : 90.69 (+0.01%)
LGND : 120.86 (-0.02%)
AMAG : 16.71 (+2.39%)
ADRO : 4.05 (+10.05%)
Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View

Ligand (LGND) beats earnings and sales estimates for the fourth quarter of 2018 and raises 2019 guidance.

LGND : 120.86 (-0.02%)
NVS : 89.88 (+0.97%)
AMGN : 188.34 (+0.89%)
RTRX : 21.56 (+0.98%)
Ligand Pharmaceuticals (LGND) Q4 Earnings and Revenues Top Estimates

Ligand (LGND) delivered earnings and revenue surprises of 33.86% and 10.01%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

LGND : 120.86 (-0.02%)
Ligand: 4Q Earnings Snapshot

SAN DIEGO (AP) _ Ligand Pharmaceuticals Inc. (LGND) on Thursday reported a loss of $42.5 million in its fourth quarter.

LGND : 120.86 (-0.02%)
Ligand Reports Fourth Quarter and Full Year 2018 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2018, and provided an operating forecast and program updates....

LGND : 120.86 (-0.02%)
Ligand Announces OmniAb(R) Partnership with Genagon Therapeutics

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb partnership with Genagon Therapeutics AB, an immuno-oncology focused biotech located in...

LGND : 120.86 (-0.02%)
Ligand Pharm Has Returned 22.9% Since SmarTrend Recommendation (LGND)

SmarTrend identified a Downtrend for Ligand Pharm (NASDAQ:LGND) on November 13th, 2018 at $152.60. In approximately 3 months, Ligand Pharm has returned 22.91% as of today's recent price of $117.64.

LGND : 120.86 (-0.02%)
Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales

Vertex's (VRTX) Q4 grows on earnings and revenue beat with rising demand for its CF products. Shares up.

CELG : 90.69 (+0.01%)
LGND : 120.86 (-0.02%)
CRSP : 31.52 (+1.91%)
VRTX : 188.07 (+1.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade LGND with:

Business Summary

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases....

See More

Key Turning Points

2nd Resistance Point 123.99
1st Resistance Point 122.43
Last Price 120.86
1st Support Level 119.71
2nd Support Level 118.55

See More

52-Week High 278.62
Fibonacci 61.8% 209.84
Fibonacci 50% 188.59
Fibonacci 38.2% 167.34
Last Price 120.86
52-Week Low 98.56

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar